ライフサイエンスコーパス: blockade

1 antileukemia immunity (vaccines, checkpoint blockade).

2 ecognition and response to immune checkpoint blockade.

3 hannel also compromised the effects of MerTK blockade.

4 t to both chemotherapy and immune checkpoint blockade.

5 T and B cell activation following anti-CD86 blockade.

6 one of these parameters were affected by RAS blockade.

7 shed by dorsal rhizotomy or by neuromuscular blockade.

8 ent with those previously observed with PD-1 blockade.

9 sistent with blockade of interneuronal NMDAR blockade.

10 on and whether that can be prevented by VEGF blockade.

11 r the antitumor effects of immune checkpoint blockade.

12 d rescue the proapoptotic effects due to FGF blockade.

13 tores the T-cell reactivity to the anti-PD-1 blockade.

14 ls most likely to benefit from costimulation blockade.

15 ection in combination with immune checkpoint blockade.

16 al antibodies, which produce a more specific blockade.

17 e, acute, and persistent targets of WIN site blockade.

18 ness of anaplastic thyroid carcinoma to PD-1 blockade.

19 cation to enhance the efficacy of PD-1/PD-L1 blockade.

20 ited to improve response rates to checkpoint blockade.

21 ated selective response to immune checkpoint blockade.

22 survival and a low rate of response to PD-1 blockade.

23 drug resistance demonstrated efficient SHP2 blockade.

24 ted T-cell infiltrates similar to checkpoint blockade.

25 spin resonance and readout using Pauli spin blockade.

26 herapeutic strategies, for example, with ASM blockade.

27 ith differential enhancement by open channel blockade.

28 our systemic AT(1)R (Ang II type-1 receptor) blockade.

29 howing single-electron tunneling and Coulomb blockade.

30 e but relatively less sensitive to endocytic blockade.

31 mbination with CTLA4Ig-based T-costimulation blockade.

32 sociated with response or resistance to PD-1 blockade.

33 tions of NMDAR-positive modulation vs. NMDAR blockade.

34 1, keratin 10, and DSC-1, is reversed by p63 blockade.

35 murine TNBC models poorly responsive to PD-1 blockade.

36 th programmed cell death-1 (PD-1) checkpoint blockade.

37 dies and predicts a clinical response to PD1 blockade.

38 bacterium tuberculosis infection upon GM-CSF blockade.

39 ative signaling mechanism that can bypass AR blockade.

40 ated with optimized renin-angiotensin system blockade.

41 cked, but unaffected by CTLA-4 activation or blockade.

42 iated with poor outcome to immune checkpoint blockade (1), this has not been comprehensively evaluate

43 s, while responsiveness to immune checkpoint blockade, a form of cancer immunotherapy, is paradoxical

44 ion, and altered MPhi polarization via IL10R blockade all reduced MT coherence and/or tumor cell elon

45 kade was remarkably more effective than PD-1 blockade alone in enhancing T cell cycling and different

46 fficacy of treatment compared to PD1 pathway blockade alone(6,7), pointing to an incomplete understan

47 llular phagocytosis beyond that of SIRPalpha blockade alone.

48 This study evaluated the combination of PD-1 blockade and CCR2 inhibition in anti-PD-1-resistant glio

49 Notably, both type I IFN receptor blockade and CD8 T cell depletion prevented infection-in

50 h clinical outcomes during immune checkpoint blockade and chimeric antigen receptor (CAR) T cell ther

51 Pharmacologic CCR2 blockade and genetic deletion of Ccr2 both resulted in s

52 Pharmacological blockade and knockdown of the melanocortin-4 receptor ge

53 -1 blockade, indicating synergy between PD-1 blockade and Siah2 loss.

54 also provide mechanistic insights about the blockade and suggest that MDIMP is a promising member of

55 e 1 conventional DCs are essential for PD-L1 blockade and they upregulate PD-L1 upon antigen uptake.

56 osomal degradation leading to autophagy flux blockade, and simultaneously caused the dissociation of

57 seroconversion for IgG (80%), IgA (78%), and blockade antibodies (87%).

58 , most notably through the use of checkpoint blockade antibodies and chimeric antigen receptor T cell

59 tic vectors engineered to express checkpoint blockade antibodies and cytokines could provide an avenu

60 trongly correlated with serum IgA titers and blockade antibodies and remained elevated 3 months after

61 dd-MPFG, and the anti-PD-1 immune checkpoint blockade antibody.

62 ombinatorial approaches involving checkpoint blockade are now standard of care in patients with advan

63 Our results suggest G-CSFR blockade as a promising therapeutic approach to attenuat

64 en identified Cx43 (connexin 43) hemichannel blockade as a robust suppressor of the abnormal phenotyp

65 ammatory phase for optimal effects of S100A9 blockade as potential immunomodulatory treatment in acut

66 Thrombin or NETosis inhibition or C5aR1 blockade attenuated platelet-mediated NET-driven thrombo

67 Strikingly, IL-6 blockade attenuates disease only in mice treated with IF

68 PD1 blockade-based combination therapy has been approved as

69 al benefit of targeted and immune checkpoint blockade-based therapies in melanoma, resistance inevita

70 Patients who received checkpoint blockade before DC vaccination had higher baseline MA-sp

71 (Renin-Angiotensin System Blockade Benefits in Clinical Evolution and Ventricular

72 SCLC who were treated with immune checkpoint blockade between June 2011 and December 2017 and who wer

73 te inhibition of PC2 function by temperature blockade, brefeldin A, chloroquine, and multiple inhibit

74 Selective I(NaL) blockade by GS967 prevents EADs and abolishes PVT in lon

75 Anti-human IL-6Ralpha blockade by tocilizumab (TCZ) has been used in pig-to-ba

76 combination with either checkpoint or CSF1R blockade caused additive antitumor activity with complet

77 ignificantly higher following combination IC blockade compared with other latency-reversing agents, i

78 herapies for PARDS: continuous neuromuscular blockade, corticosteroids, inhaled nitric oxide (iNO), p

79 ent within keloid tumors and that HIF-1alpha blockade could be a novel avenue of treatment for these

80 Interestingly, IL33 blockade did not affect bone marrow-derived expansion an

81 PD-1 blockade diminishes exhaustion and improves GVL, while b

82 Conversely, selective IFN receptor blockade effectively diminished the ongoing microgliosis

83 signaling inhibition, and immune checkpoint blockade effectively restores antitumor immunity and res

84 hibition of PGE2 synthesis and PGE2 receptor blockade enhanced bacterial killing in Mphis.

85 Blockade ERK1/2 activation by PD98059 attenuated these s

86 data establish that combining CCR2 and PD-1 blockade extends survival in clinically relevant murine

87 However, TAM blockade failed to decrease tumor progression due to a c

88 Suspending CSF1R blockade following ablation enabled spontaneous macropha

89 Mutyh-deficient (Mutyh (-/-)) MEFs, but this blockade had no additive cytotoxicity in WT MEFs, sugges

90 Pharmacological immune checkpoint blockade has revolutionized oncological therapies, and i

91 through neprilysin and angiotensin receptor blockade, has led to groundbreaking findings in HFrEF.

92 gnificantly longer OS was observed with HER2 blockade (hazard ratio, 0.58; 95% CI, 0.34 to 0.97).

93 al) immunotherapy in the era of PD-1 pathway blockade, highlighting particular considerations for bio

94 Treatment with immune checkpoint blockade (ICB) has revolutionized cancer therapy.

95 anding clinical results of immune checkpoint blockade (ICB) in melanoma and other cancers, clinical t

96 Immune checkpoint blockade (ICB) is efficacious in many diverse cancer typ

97 Immune checkpoint blockade (ICB) therapy has improved patient survival in

98 mplicated in resistance to immune checkpoint blockade (ICB) therapy(1-3).

99 metabolic inhibitors with immune checkpoint blockade (ICB), chemotherapy, radiation, and/or diet now

100 e to immunotherapy such as immune checkpoint blockade (ICB).

101 y and improved efficacy of immune checkpoint blockade (ICB).

102 cancer (TNBC) does not respond to checkpoint blockade immunotherapy as a result of immunosuppressive

103 the complications resulting from checkpoint blockade immunotherapy in cancer patients, yet the under

104 The advent of checkpoint blockade immunotherapy over the past few years represent

105 breast cancer and facilitate the checkpoint blockade immunotherapy.

106 y heightens sensitivity to immune checkpoint blockade in a murine model of melanoma.

107 a response-adaptive strategy for checkpoint blockade in advanced RCC.

108 nonhuman primate model, we tested complement-blockade in BD donors to prevent DGF and improve graft s

109 y-induced weight loss, and immune checkpoint blockade in cancer.

110 ive to a Nup62-mediated nuclear pore complex blockade in cells that potently block infection by wild-

111 The efficacy of interleukin-6 receptor blockade in hospitalized patients with coronavirus disea

112 risingly, early life neuroestrogen synthesis blockade in NCM enhanced the neural representations of b

113 vaccine, NEO-PV-01, in combination with PD-1 blockade in patients with advanced melanoma, non-small c

114 ated by iAs through specific autophagic flux blockade in progenitor cells, which may have potential t

115 vide therapeutic proof of principle for FEN1 blockade in tamoxifen-resistant breast cancer.

116 Neither early-life adversity nor CRHR1 blockade in the adult influenced anxiety- or depression-

117 metastases to determine the activity of PD-1 blockade in the CNS.

118 induced senescent cells to immune checkpoint blockade in vivo.

119 We show that distinct current blockades in wild-type aerolysin can be used to identify

120 Markers sensitive to cyclo-oxygenase-1 blockade, including platelet reactivity in response to a

121 Intriguingly, Tim-3 knockdown and Tim-3 blockade increased HIV-1 replication in primary CD4(+) T

122 Tim-3 blockade increases HIV-1 replication, suggesting a poten

123 hibited in Siah2(-/-) mice subjected to PD-1 blockade, indicating synergy between PD-1 blockade and S

124 n response to programmed cell death 1 (PD-1) blockade induced a programmed death ligand 1/NOD-, LRR-,

125 Thus, despite CTLA-4/PD-1 blockade inducing robust latency reversal and reducing t

126 lls appear as primary sensors of cholinergic blockade inducing the expansion of tuft cells, which ado

127 Antibody- or shRNA-mediated functional ABCB5 blockade inhibited proliferation and survival of GBM cel

128 Additionally, integrin blockade inhibited tECM-driven TGFBR2 expression, while

129 Mechanistically, we demonstrate that ABCB5 blockade inhibits TMZ-induced G(2)/M arrest and augments

130 The majority of irAEs from checkpoint blockade involve either barrier tissues (e.g., gastroint

131 eliable biomarkers of response to checkpoint blockade is crucial to facilitate improvements in the cl

132 PD-1 blockade is highly effective in classical Hodgkin lympho

133 Immune checkpoint blockade is one of the most promising strategies of canc

134 with their wild-type counterparts, and OX40 blockade led to a significant reduction in the EAE sever

135 riven by nasal respiration, unilateral naris blockade led to an ipsilateral reduction in ketamine-dep

136 rophages and an enhanced effect of anti-CD47 blockade limiting tumor growth in TMEM30A-knockout model

137 Thus, peripheral CB1R blockade may allow safely potentiating the antiobesity a

138 2.6 complex stabilization and Ca(2+) release blockade may be potentially beneficial for the treatment

139 se data suggest that combined CXCR4 and PD-1 blockade may expand the benefit of chemotherapy in PDAC

140 ell death-1 (PD-1)/programmed death ligand-1 blockade may potentially augment graft-vs-tumor effects

141 t regulate this process, and whether LTbetaR blockade might be of therapeutic value have remained unc

142 Dual blockade of 2 miRNAs can act synergistically to increase

143 Similarly, long-term blockade of action potentials and Ca(2+) entry did not d

144 Consequently, blockade of alpha(IIb)beta(3) or genetic loss of GPVI re

145 Blockade of alpha5-GABARs accelerates reversal learning,

146 These results suggest that blockade of angiotensin II AT(1) receptors has a major i

147 Blockade of AP activation by anti-C3b or CFB mAbs also e

148 little compensation for lack of inhibition (blockade of APL).

149 ons with cells from WT and Asm(-/-) mice and blockade of Asm with amitriptyline.

150 In the non-aging H. vulgaris animals, the blockade of autophagy by knocking down WIPI2 suffices to

151 The blockade of autophagy maturation and promotion of polypl

152 The presumed mode of action is via blockade of axonal voltage gated potassium channels, the

153 Moreover, pharmacologic blockade of B-family DNA polymerases using aphidicolin o

154 l IL-4/IL-13 inhibition, we demonstrate that blockade of both IL-4 and IL-13 is required to broadly b

155 Blockade of C5a receptor 1 synergized with antiangiogeni

156 These increases are prevented by blockade of Ca(2+) channels and depend on downstream rec

157 Blockade of CD79A or CD79B ubiquitination or Cbls ligase

158 LS) showed a variable response from complete blockade of cell growth to absolute resistance.

159 Providing clinically effective blockade of CGRP signaling required surmounting multiple

160 Blockade of CXCL1 inhibited the recruitment and aggregat

161 In contrast, mobilization-inducing blockade of CXCL12 receptor CXCR4 and integrins rapidly

162 sive chemokine receptor CXCR4, and selective blockade of CXCR4 reduced or eliminated the early glucoc

163 tosis in megakaryocyte differentiation where blockade of cytokinesis is an essential step.

164 Absence (in Sele(-/-) hosts) or therapeutic blockade of E-selectin using small molecule mimetic GMI-

165 g Type II cells and were abolished following blockade of either Cav(L) or ANO1.

166 Pharmacological blockade of ER stress in vitro using dexamethasone or th

167 In DCs, blockade of ERK signaling similarly inhibited IL-10 expr

168 In contrast, pharmacological blockade of estrogen synthesis or nuclear estrogen recep

169 Blockade of G-CSF restored normal granulopoiesis in Delt

170 The blockade of GABA(A) receptors strongly improved the sele

171 Early blockade of glial xCT activity inhibited later seizures,

172 proteins, no longer promoted migration upon blockade of Golgi trafficking.

173 As such, blockade of GPR81 signaling could boost cancer immunothe

174 Furthermore, an in vitro blockade of granzyme B was observed to decrease TNF prod

175 demonstrate that Netrin-1 can substitute for blockade of Gsk3alpha/beta and Mek1/2 to sustain self-re

176 Pharmacological blockade of HCN and SK activities mimicked changes in fi

177 hagocytosis of zymosan in vivo, and antibody blockade of IFN-gamma after endotoxemia improved surviva

178 Blockade of IFN-gamma signaling in mice increases lesion

179 pithelium, which was reversed by therapeutic blockade of IFN-gamma.

180 the inhibition of glucocorticoids synthesis, blockade of IL-17A, or depletion of the Th17 cell-induci

181 d interleukin-18 (IL-18) production, whereas blockade of IL-18 receptor in the brain helped protect a

182 In human PBMCs, we have demonstrated that blockade of IL-4/IL-13 signaling aborted IgE production

183 Peripheral cholinergic blockade of immune reactions fine-tunes this immune resp

184 cells into the tumor microenvironment (TME), blockade of inhibitory receptors that limit NK cell func

185 of 1440 mg AV-101 in humans, consistent with blockade of interneuronal NMDAR blockade.

186 Blockade of ionotropic glutamate receptors in the DMH, o

187 ration elicited by hypoxia was blunted after blockade of ionotropic glutamatergic receptors at the le

188 Moreover, blockade of ISR activation prevented the behavioral abno

189 imer on the lysosome accumulate Ub-Rheb, and blockade of its degradation instigates robust lysosomal

190 in acute respiratory distress syndrome, the blockade of its receptor with tocilizumab (TCZ) could re

191 type-2 cytokine-mediated gene repression and blockade of KC differentiation are multifactorial, invol

192 Pharmacologic blockade of Kcnn2 improves these learning deficits, sugg

193 to enhance endogenous fibrinolysis, whereas blockade of leukocyte interaction with the vessel wall i

194 We thus hypothesized that blockade of LRT-induced immunosuppressive responses coul

195 Further, blockade of matrix metalloprotease with BB-94 inhibited

196 Blockade of MerTK resulted in accumulation of apoptotic

197 with negative control (P <= 0.05) and single blockade of miR-24-3p (P <= 0.01) or miR-145-5p (P <= 0.

198 Dual blockade of miR-24-3p and miR-145-5p represents a novel

199 Irreversible blockade of MORs in the VTA counteracted two drug-seekin

200 More importantly, blockade of NFkappaB signaling completely reversed eleva

201 previously shown that in male mice transient blockade of NMDA receptors (NMDARs) during development [

202 The blockade of NMDA receptors resulted in a slight enhancem

203 mice, the genetic deletion of Notch3 or the blockade of NOTCH3 signalling attenuates inflammation an

204 Nox4 in skeletal muscles or pharmacological blockade of Nox4 activity abrogated tumor-induced cachex

205 These data indicate that blockade of NRP1, a unique 'immune memory checkpoint', m

206 This was associated with blockade of nuclear factor-kappaB pathway signaling, res

207 Immunotherapy is primarily based on blockade of one or two immune checkpoints and has a lowe

208 ha, vegf3r, and vegfaa mRNA were enhanced by blockade of P2RX7 immediately after injury, indicating h

209 baroreflex gain by 40% (p = 0.031), whereas blockade of P2Y(1) receptors increased baroreflex gain b

210 o convey itch information and suggest that a blockade of PAR2 or TRPV3 individually or both may serve

211 asis on precision medicine approaches to the blockade of pathways involved in allergic diseases.

212 Consequently, therapeutic blockade of PD-1 enhances T cell-mediated anti-tumor imm

213 Dual blockade of PD-L1 and VEGF has enhanced anticancer immun

214 Blockade of programmed death-ligand 1 (PD-L1) by therape

215 Pharmacological blockade of prostaglandin E(2) biosythesis favors CD103(

216 binding by the SHP2 active site, leading to blockade of RasGAP binding and optimal signaling by the

217 lopment of IL-1 blocking agents, therapeutic blockade of select IL-1 family members for periodontitis

218 vious work has demonstrated that therapeutic blockade of single miRNAs is possible.

219 Therefore, it seems that blockade of such molecules facilitates the T cells activ

220 9 increased levels of GluA1 in the mPFC and, blockade of such receptors by direct administration of N

221 Preclinical studies indicate that blockade of the alpha5 subtype of the GABA receptor (alp

222 ings provide a rationale for pharmacological blockade of the AXL signaling axis in PIK3R2-amplified o

223 ces host immune defense, suggesting that the blockade of the beta2-AR signaling could be used to incr

224 tor-blocking antibody to induce a short-term blockade of the IFN-I pathway.

225 We conclude that early blockade of the IL-1 receptor is therapeutic in acute hy

226 using inhibition of IDO1 in combination with blockade of the PD1 pathway in patients with melanoma di

227 plasmic transport protein sequestration, nor blockade of the phenylalanine-glycine (FG)-rich nuclear

228 tant interneurons, and is rescued by genetic blockade of the pro-apoptotic factor BAX.

229 hese gaps, in this study, we investigated if blockade of the TLR4-MD2 complex impacts BP and vascular

230 AML cell proliferation, and pharmacological blockade of the vitamin B6 pathway at both PDXK and PLP

231 In vivo silencing of Mcl and Mincle or blockade of their endogenous ligand SAP130 revealed that

232 death 1 (PD1) inhibits T cell responses, and blockade of this interaction has proven to be an effecti

233 Blockade of this Nedd8 clearance pathway with MLN4924 ca

234 iminishes exhaustion and improves GVL, while blockade of Tim-3, TIGIT or LAG3 is ineffective.

235 Furthermore, co-blockade of TIM3 and programmed cell death 1 (PD1) can r

236 this surrogate, especially when coupled with blockade of TNFalpha signaling, expanded VAT-Treg cells,

237 n synthesis but sensitive to pharmacological blockade of transforming protein RhoA activity.

238 Blockade of TrkA by 1-NM-PP1 enhanced eosinophil spreadi

239 ch are rescued by genetic or pharmacological blockade of TRPV4 channel activity.

240 Blockade of TRPV4 channels with the selective TRPV4 bloc

241 Blockade of vascular endothelial growth factor A (VEGFA)

242 acts cooperatively with anti-PD-1 checkpoint blockade, offering a combination immunotherapy strategy

243 h is opposite to the effect of ERK signaling blockade on IL-12/23p40 in macrophages.

244 tion and invasion rates because of autophagy blockade only in BRAF(V600E)-mutant melanoma cells.

245 Unexpectedly, pharmacological blockade or genetic deletion of CB1, CB2, or GPR55 recep

246 Blockade or knockdown of GM-CSF can partially reduce imm

247 Therapeutic IL-1-receptor blockade or NLRP3-inhibition reduces myeloproliferation

248 eal intubations without use of neuromuscular blockade (p < 0.001).

249 In vivo CXCR3 blockade partially abrogates the survival advantage of a

250 PD-1 within the tumor, but not acute ex vivo blockade, partially restored cell couple maintenance and

251 unotherapy, which includes immune checkpoint blockade, personal neoantigen vaccines, and adoptive T c

252 features of huwentoxin involved in Na(v)1.7 blockade, provide a foundation for additional optimizati

253 Here, we propose a setup based on Pauli spin blockade (PSB) for the preparation of large-scale W stat

254 Although CGRP receptor blockade reduced certain proinflammatory gene expression

255 Bilateral nares blockade reduced ketamine-induced hyperactivity and HFO

256 odent studies indicate that ghrelin receptor blockade reduces alcohol consumption.

257 her, we demonstrate that systemic PKCepsilon blockade reduces asthmatic respiratory distress in respo

258 on of sympathetic nerve activity and beta2AR blockade reduces these cells and prevents the blood pres

259 mproved outcomes under PD1 immune checkpoint blockade relative to APOE2 mice, and patients carrying A

260 ies related to innate responses such as CD47 blockade rely on the rapid immune responses within the t

261 Clinical studies with IL17 and checkpoint blockade represent a novel combinatorial therapy with po

262 Immune checkpoint blockade represents a promising approach in oncology, sh

263 ing glutamine metabolism rendered checkpoint blockade-resistant tumors susceptible to immunotherapy.

264 n a breast cancer cell line MDA-MB-231 NMDAR blockade results in an increase in endosomal size and de

265 Drug-mediated K(v)11.1 blockade results in AP prolongation, which poses an incr

266 electrocardiograms containing basal and ANS-blockade segments.

267 We describe the characterization of nanopore blockade sensing of PSA by (1) tuning on/off the electro

268 s in determining the performance of nanopore blockade sensing system, where prostate-specific antigen

269 hereas increasing [GABA] through GABA uptake blockade shortens it.

270 nanoparticles in combination with checkpoint blockade significantly reduced tumor growth over time an

271 Costimulatory blockade strategies that include corticosteroids have re

272 rcinoma (PDAC) responds poorly to checkpoint blockade, such as anti-CTLA-4 and anti-PD-1.

273 sensitivity of HR(+) 59-2-HI tumor to PD-L1 blockade, suggesting that antiprogestins may improve imm

274 Further, while systemic estrogen synthesis blockade suppressed juvenile song production, neither sy

275 Conclusion: PSMA RNT and PD-1 blockade synergistically improve therapeutic outcomes in

276 BACKGROUNDThe recent failure of checkpoint-blockade therapies for glioblastoma multiforme (GBM) in

277 Immune checkpoint blockade therapies have extended patient survival across

278 Immune checkpoint blockade therapies have shown clinical promise in a vari

279 a new mechanism for the resistance to PD-L1 blockade therapy in multiple cancers, including PCa.

280 BMI1 eliminated BMI1(+) CSCs and enabled PD1 blockade therapy, resulting in the inhibition of metasta

281 le that are potentially reversible with beta-blockade therapy.

282 nefit from PD1 and/or PDL1 immune checkpoint blockade therapy.

283 from immune attack, and sensitivity to PD-1 blockade therapy.

284 rs correlated with long-term benefit of PD-1 blockade therapy.

285 targeting BMI1 may enable immune checkpoint blockade to inhibit metastatic tumor growth and prevent

286 re, we use an inducible nuclear pore complex blockade to monitor the kinetics of HIV-1 nuclear import

287 Notably, TAK1 blockade upregulated expression of p53 target genes in c

288 T(FH) cells were decreased by costimulation blockade using the CTLA-4-immunoglobulin (Ig) fusion pro

289 outcomes of sarcomatoid tumors to checkpoint blockade versus antiangiogenics alone, and develop perso

290 ablation of choroidal macrophages via CSF1R blockade was associated with choroidal vascular atrophy

291 Dual blockade was remarkably more effective than PD-1 blockad

292 Continuous neuromuscular blockade was the most common, used in 31%, followed by i

293 For pharmacological blockade, we engineered a bispecific receptor decoy by a

294 y sensitive to SHP2 inhibition or checkpoint blockade were particularly susceptible.

295 r absence of pharmacologic sigma(1) receptor blockade with FTC146.

296 ved survival and a high response rate to PD1 blockade with pembrolizumab in a phase 2 clinical trial.

297 ut of the serotonin transporter or postnatal blockade with selective serotonin reuptake inhibitors (S

298 te synergistic efficacy of immune checkpoint blockade with the MDSC-diminishing drugs cabozantinib or

299 Renal perfusion/flow improved with CD47 blockade, with a corresponding reduction in oxidative st

300 model of binge-eating in female rats, RXFP3 blockade within the PVN prevented binge-eating behavior.